Table 1 Age and tumor characteristics for prostate cancer patients referred for radiation therapy at Korle Bu teaching hospital during 2003-2009
Characteristic | Overall cohort (n=379) | Organ-confined cohort (n=251) | FFbF analysis cohort (n=52) |
|---|---|---|---|
n (%) | n (%) | n (%) | |
Age, Y | Â | ||
<60 | 78 (20.6) | 55 (21.9) | 10 (19.2) |
60-64 | 89 (23.5) | 66 (26.3) | 13 (25.0) |
65-69 | 95 (25.1) | 69 (27.5) | 17 (32.7) |
70-74 | 76 (20.1) | 46 (18.3) | 9 (17.3) |
>74 | 41 (10.8) | 15 (6.0) | 3 (5.8) |
iPSA ng/ml | Â | ||
0-10.0 | 50 (13.2) | 46 (18.3) | 9 (17.3) |
10.1-20.0 | 50 (13.2) | 47 (18.7) | 10 (19.2) |
20.1-50.0 | 79 (20.8) | 61 (24.3) | 16 (30.8) |
50.1-100.0 | 70 (18.5) | 45 (17.9) | 11 (21.2) |
100.1-1000.0 | 73 (19.3) | 40 (15.9) | 5 (9.6) |
>1000 | 7 (1.9) | 2 (0.8) | 1 (1.9) |
Unknown | 50 (13.2) | 10 (4.0) | -- |
Gleason Score | Â | ||
≤6 | 130 (34.3) | 114 (45.4) | 25 (48.1) |
7 | 102 (26.9) | 81 (32.3) | 20 (38.5) |
8 to 10 | 71 (18.7) | 40 (15.9) | 5 (9.6) |
Unknown | 76 (20.1) | 16 (6.4) | 2 (3.9) |
Clinical T stage | Â | ||
T1 | 17 (4.5) | 17 (6.8) | -- |
T2 | 114 (30.1) | 114 (45.4) | 22 (42.3) |
≥T3 | 77 (20.3) | 77 (30.7) | 29 (55.8) |
Tx | 43 (11.4) | 43 (17.1) | 1 (1.9) |
M | 128 (33.8) | -- | -- |
Risk Group | Â | ||
Low | -- | 20 (8.0) | 4 (7.7) |
Intermediate | -- | 48 (19.1) | 9 (17.3) |
High | -- | 166 (66.1) | 39 (75.0) |
Unknown | -- | 17 (6.8) | -- |